Forward Pharma A/S (NASDAQ:FWP – Get Rating) and Avalo Therapeutics (NASDAQ:AVTX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Profitability

This table compares Forward Pharma A/S and Avalo Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Forward Pharma A/S and Avalo Therapeutics, as provided by MarketBeat.

Institutional and Insider Ownership

13.0% of Forward Pharma A/S shares are held by institutional investors. 71.5% of Forward Pharma A/S shares are held by company insiders. Comparatively, 45.4% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Forward Pharma A/S has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Earnings & Valuation

This table compares Forward Pharma A/S and Avalo Therapeutics' top-line revenue, earnings per share and valuation.

Forward Pharma A/S has higher earnings, but lower revenue than Avalo Therapeutics.

Summary

Forward Pharma A/S beats Avalo Therapeutics on 7 of the 10 factors compared between the two stocks.

About Forward Pharma A/S

(Get Rating)

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

About Avalo Therapeutics

(Get Rating)

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.